Chen TongShuai

Dr. Chen TongShuai

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2020 in IEEE Transactions on Instrumentation and Measurement
Verified
Journal Article
Closed access
CMCaiyun Ma
Caiyun Ma
SWShoushui Wei
Shoushui Wei
CTChen TongShuai
Chen TongShuai
JZJingquan Zhong
Jingquan Zhong
ZLZhenhua Liu
Zhenhua Liu
CLChengyu Liu
Chengyu Liu
Atrial fibrillation (AF) can cause a variety of heart diseases and its detection is insufficient in outside hospital. We proposed three methods for AF diagnosis in ambulatory settings. The first method is a convolutional neural network (CNN) trained on modified frequency slice wavelet transform (MFSWT) data. The second is a support vector machine (SVM) classifier trained on multiple AF features data. The third method is an SVM trained on the same feature set but extended by the predictive probability of the CNN. The proposed method (the third one) achieved the highest detection accuracy. MIT-BIH AF database was used as a training set with an accuracy of 97.87% for 30-s ECG episodes and 96.09% for 10-s ECG episodes from fivefold cross-validation. The trained model was tested on the PhysioNet/Computing in Cardiology (CinC) Challenge 2017 database, achieving an accuracy of 93.21% for 30-s episodes and 93.03% for 10-s ECG episodes. When tested on the China Physiological Signal Challenge (CPSC) 2018 database, the corresponding accuracies were 98.48% and 98.61%. The results on the wearable ECGs from a clinical AF patient were 99.21% and 97.04%. We retrained the model on the PhysioNet/CinC Challenge 2017 data set and tested on the other database to explore the generalization ability of the proposed method. Corresponding test results on the MIT-BIH AF database showed accuracies of 96.84% and 95.13%, on the CPSC 2018 database were 96.21% and 98.45%, on the wearable ECGs were 99.08% and 96.43%. The results proved that the proposed method could provide high accuracy and reliable recognition for AF events.

30 July 2015 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
HLHui Liu
Hui Liu
CTChen TongShuai
Chen TongShuai
NLNa Li
Na Li
SWShujian Wang
Shujian Wang
PBPeili Bu
Peili Bu
SIRT3, a member of the sirtuin family of NAD+-dependent deacetylases, resides primarily in the mitochondria and has been shown to deacetylate several metabolic and respiratory enzymes that regulate important mitochondrial functions. Previous researches show an important role of SIRT3 in regulating the production of reactive oxygen species (ROS), and highlight the ability of SIRT3 to protect cells from oxidative damage. A key substance of renin-angiotensin-aldosterone system (RAAS), Angiotensin II (AngII) can induce cells dysfunction by increasing the production of ROS. In this paper, we focus on the role of SIRT3 in AngII-induced human umbilical vein endothelial cells (HUVECs) dysfunction. To study the influence of AngII on SIRT3 expression, HUVECs were treated with AngII of 10−7, 10−6, 10−5 mol/L for 24 h. SIRT3 expression was detected by wester-blotting analysis and RT-PCR. In addition, to research the role of SIRT3 in AngII-induced HUVECs,we used SIRT3 siRNA to knock down SIRT3 expression in HUVECs. Cells pretreated with negative control siRNA or SIRT3 siRNA were exposed to AngII for 24 h, and endothelial nitric oxide synthase (eNOS) expression, eNOS activity, total level of nitric oxide (NO) and ROS generation of each group were detected. Here we show that AngII treatment could increase generation of ROS, and decrease eNOS activity and total level of NO, while upregulated eNOS expression as a compensatory mechanism. The stimulation of AngII upregulated the expression of SIRT3 in HUVECs. SIRT3 siRNA worsen the AngII-induced effects above, besides, downregulated eNOS protein expression. These data suggest that SIRT3 plays a role of protection in AngII-induced HUVECs dysfunction via regulation of ROS generation.

2 September 2016 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
HSHongyan Su
Hongyan Su
JLJingyuan Li
Jingyuan Li
CTChen TongShuai
Chen TongShuai
NLNa Li
Na Li
JXjie xiao
jie xiao
PBPeili Bu
Peili Bu

3 May 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
MSMengying Suo
Mengying Suo
YQYan Qi
Yan Qi
LLLingxin Liu
Lingxin Liu
CZChunmei Zhang
Chunmei Zhang
JLJingyuan Li
Jingyuan Li
PBPeili Bu
Peili Bu
Heart failure caused by pressure overload is one of the leading causes of heart failure worldwide, but its pathological origin remains poorly understood. It remains critical to discover and find new improvements and treatments for pressure overload-induced heart failure. According to previous studies, mitochondrial dysfunction and myocardial interstitial fibrosis are important mechanisms for the development of heart failure. The oligopeptide Szeto-Schiller Compound 31 (SS31) can specifically interact with the inner mitochondrial membrane and affect the integrity of the inner mitochondrial membrane. Whether SS31 alleviates pressure overload-induced heart failure through the regulation of mitochondrial fusion has not yet been confirmed. We established a pressure-overloaded heart failure mouse model through TAC surgery and found that SS31 can significantly improve cardiac function, reduce myocardial interstitial fibrosis, and increase the expression of optic atrophy-associated protein 1 (OPA1), a key protein in mitochondrial fusion. Interestingly, the role of SS31 in improving heart failure and reducing fibrosis is inseparable from the presence of sirtuin3 (Sirt3). We found that in Sirt3KO mice and fibroblasts, the effects of SS31 on improving heart failure and improving fibroblast transdifferentiation were disappeared. Likewise, Sirt3 has direct interactions with proteins critical for mitochondrial fission and fusion. We found that SS31 failed to increase OPA1 expression in both Sirt3KO mice and fibroblasts. Thus, SS31 can alleviate pressure overload-induced heart failure through Sirt3-mediated mitochondrial fusion. This study provides new directions and drug options for the clinical treatment of heart failure caused by pressure overload.

1 March 2024 in Thrombosis Journal
Verified
Journal Article
Open access
PDF file
THTong Hu
Tong Hu
CCChangli Chen
Changli Chen
KMKellina Maduray
Kellina Maduray
WHWenqiang Han
Wenqiang Han
CTChen TongShuai
Chen TongShuai
JZJingquan Zhong
Jingquan Zhong
Background and objective: Left ventricular thrombus (LVT) formation in patients with acute myocardial infarction (AMI) or cardiomyopathies is not uncommon. The optimal oral anticoagulation therapy for resolving LVT has been under intense debate. Vitamin K antagonists (VKAs) remain the anticoagulant of choice for this condition, according to practice guidelines. Evidence supporting the use of direct oral anticoagulants (DOACs) in the management of LVT continues to grow. We performed a systematic review and meta-analysis to compare the efficacy and safety of DOACs versus VKAs. Methods: A comprehensive literature search was carried out in PubMed, Cochrane Library, Web of Science, Embase, and Scopus databases in July 2023. The efficacy outcomes of this study were thrombus resolution, ischemic stroke, systemic embolism, stroke/systemic embolism, all-cause mortality, and adverse cardiovascular events. The safety outcomes were any bleeding, major bleeding, and intracranial hemorrhage. A total of twenty-seven eligible studies were included in the meta-analysis. Data were analyzed utilizing Stata software version 15.1. Results: There was no significant difference between DOACs and VKAs with regard to LVT resolution (RR = 1.00, 95% CI 0.95–1.05, P = 0.99). In the overall analysis, DOACs significantly reduced the risk of stroke (RR = 0.74, 95% CI 0.57–0.96, P = 0.021), all-cause mortality (RR = 0.70, 95% CI 0.57–0.86, P = 0.001), any bleeding (RR = 0.75, 95% CI 0.61–0.92, P = 0.006) and major bleeding (RR = 0.67, 95% CI 0.52–0.85, P = 0.001) when compared to VKAs. Meanwhile, in the sub-analysis examining randomized controlled trials (RCTs), the aforementioned outcomes no longer differed significantly between the DOACs and VKAs groups. The incidences of systemic embolism (RR = 0.81, 95% CI 0.54–1.22, P = 0.32), stroke/systemic embolism (RR = 0.85, 95% CI 0.72–1.00, P = 0.056), intracranial hemorrhage (RR = 0.59, 95% CI 0.23–1.54, P = 0.28), and adverse cardiovascular events (RR = 0.99, 95% CI 0.63–1.56, P = 0.92) were comparable between the DOACs and VKAs groups. A subgroup analysis showed that patients treated with rivaroxaban had a significantly lower risk of stroke (RR = 0.24, 95% CI 0.08–0.72, P = 0.011) than those in the VKAs group. Conclusion: With non-inferior efficacy and superior safety, DOACs are promising therapeutic alternatives to VKAs in the treatment of LVT. Further robust investigations are warranted to confirm our findings.

16 April 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LLLing-Xin Liu
Ling-Xin Liu
XZXue-Hui Zheng
Xue-Hui Zheng
JHJing-Han Hai
Jing-Han Hai
CZChun-Mei Zhang
Chun-Mei Zhang
YTYun Ti
Yun Ti
PBPeili Bu
Peili Bu
Cardiac remodeling is the primary pathological feature of chronic heart failure (HF). Exploring the characteristics of cardiac remodeling in the very early stages of HF and identifying targets for intervention are essential for discovering novel mechanisms and therapeutic strategies. Silent mating type information regulation 2 homolog 3 (SIRT3), as a major mitochondrial nicotinamide adenine dinucleotide (NAD)-dependent deacetylase, is required for mitochondrial metabolism. However, whether SIRT3 plays a role in cardiac remodeling by regulating the biosynthesis of mitochondrial cardiolipin (CL) is unknown. In this study, we induced pressure overload in wild-type (WT) and SIRT3 knockout (SIRT3−/−) mice via transverse aortic constriction (TAC). Compared with WT mouse hearts, the hearts of SIRT3−/− mice exhibited more-pronounced cardiac remodeling and fibrosis, greater reactive oxygen species (ROS) production, decreased mitochondrial-membrane potential (ΔΨm), and abnormal mitochondrial morphology after TAC. Furthermore, SIRT3 deletion aggravated TAC-induced decrease in total CL content, which might be associated with the downregulation of the CL synthesis related enzymes cardiolipin synthase 1 (CRLS1) and phospholipid-lysophospholipid transacylase (TAFAZZIN). In our in vitro experiments, SIRT3 overexpression prevented angiotensin II (AngII)- induced aberrant mitochondrial function, CL biosynthesis disorder, and peroxisome proliferator-activated receptor gamma (PPARγ) downregulation in cardiomyocytes; meanwhile, SIRT3 knockdown exacerbated these effects. Moreover, the addition of GW9662, a PPARγ antagonist, partially counteracted the beneficial effects of SIRT3 overexpression. In conclusion, SIRT3 regulated PPARγ-mediated CL biosynthesis, maintained the structure and function of mitochondria, and thereby protected the myocardium against cardiac remodeling.